AUTHOR=Zhang Hao , Zhu Shuangli , Deng Wanjun , Li Rui , Zhou Haiting , Xiong Huihua 

TITLE=The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook

JOURNAL=Frontiers in Immunology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.887471

DOI=10.3389/fimmu.2022.887471

ISSN=1664-3224

ABSTRACT=Chimeric antigen receptor-T (CAR-T) cell therapy is a revolutionary adoptive cell therapy, which could modify the T cells to redirect specific tumor cells. Since the CAR-T cells therapy product was first approved for B cell-derived malignancies in 2017, it has yielded unprecedented progress in hematological tumors, and dramatically reshaped the landscape of cancer therapy in recent years. Currently, accumulative evidence has demonstrated that CAR-T cell therapy could be a viable therapeutic strategy for solid cancers. However, owing to the immunosuppressive tumor microenvironment (TME) and heterogenous tumor antigens, the application of CAR-T cell therapy against solid cancers requires circumventing more challenging obstacles. Breast cancer is characterized by a high degree of invasiveness, malignancy, and poor prognosis. The review highlighted the underlying targets of CAR-T cell therapy in breast cancer, summarized the hurdles that CAR-T cell therapy encountered, and proposed the management strategies towards these challenges, which provides a novel approach in breast cancer treatment.